Neumora Therapeutics Inc (NMRA) COM USD0.0001

Sell:$1.91Buy:$1.92$0.08 (4.03%)

NASDAQ:1.35%
Market closed | Prices delayed by at least 15 minutes
Sell:$1.91
Buy:$1.92
Change:$0.08 (4.03%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$1.91
Buy:$1.92
Change:$0.08 (4.03%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.

Key people

Paul L. Berns
Executive Chairman of the Board, Co-Founder
Henry O. Gosebruch
President, Chief Executive Officer, Director
Carol Suh
Co-Founder, Chief Operating Officer
Joshua Pinto
Chief Financial Officer
Daljit Singh Aurora
Chief Strategy Officer
Jason G. Duncan
Chief Legal Officer
Robert Lenz
Head - Research and Development
Kristina M. Burow
Independent Director
Matthew K. Fust
Independent Director
Alaa A. Halawa
Independent Director
Maykin Ho
Independent Director
David Piacquad
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US6409791000
  • Market cap
    $311.81m
  • Employees
    108
  • Shares in issue
    161.56m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.